Ciulla Thomas 4
4 · Clearside Biomedical, Inc. · Filed Jan 20, 2022
Insider Transaction Report
Form 4
Ciulla Thomas
Chief Medical Officer
Transactions
- Sale
Common Stock
2022-01-19$2.13/sh−9,050$19,277→ 295,260 total - Award
Stock Option (Right to Buy)
2022-01-18+131,250→ 131,250 totalExercise: $2.19Exp: 2032-01-18→ Common Stock (131,250 underlying) - Award
Common Stock
2022-01-18+43,750→ 299,310 total
Footnotes (4)
- [F1]These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
- [F2]The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- [F3]Includes 5,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021.
- [F4]One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.